Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker-Directed Treatment in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC: A Prospective, Multi-cohort, Interventional Study (REVIVE)

NCT07279935 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07279935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07279935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker-Directed Treatment in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC: A Prospective, Multi-cohort, Interventional Study (REVIVE)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Recruiting
Start date
May 26, 2026
Completion date
May 18, 2030
Enrollment
100 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer